StemCyte, Inc., a privately-held stem cell therapy and cord blood company, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently released its 500th cord blood stem cell shipment for transplant.

This marks another milestone in the company’s rapid growth as one of the world’s leading providers of quality cord blood stem cell products. StemCyte has now provided cord blood stem cell shipments to over 130 transplant centers worldwide across 6 continents, with the number of
shipments released for transplantation increasing rapidly. StemCyte’s therapeutic products have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders.

To find out more visit StemCyte online at http://www.stemcyte.com.

CONTACT:

David Carmel
StemCyte, Inc.
917-414-4121

SOURCE StemCyte, Inc.


  • Unique Population of Stem Cells Safely Isolated From Cord Blood Using Aldesort
  • Cord Blood Banking Drive in India
  • First Hospital-Based Family Cord Blood Banking Program
  • Family Cord Blood Banking Milestone
  • Umblical Cord Blood Banking is Coming Up Very Fast in India
  • Canada's First Umbilical Cord Tissue Stem Cell Bank
  • Newborn Babies Saves Life With Umbilical Cord Blood Donation
  • Stem Cell-Rich Umbilical Cord Blood is a Life Saver
  • Stem Cell Transplant Insurance Available for Cord blood Banking Customers
  • Stem Cell Transplantation Cost in India Could Come Down in Near Future